Drugs / AJ1-11095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06343805 | Oct 2024 → Oct 2026 expected | myelofibrosis, primary myelofibrosis | Ajax Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-13 | Eli Lilly and Company | Results Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting lilly.com ↗
With an encouraging safety profile, meaningful spleen size reduction, symptom improvement, and decrease in underlying mutant disease burden, these data, while early, point to the potential to meaningfully impact treatment options for people with certain myeloproliferative neoplasms. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-13 | Eli Lilly and Company | Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting lilly.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AJ1-11095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343805 ↗ |
| Action | Inhibit | “Type II JAK2 inhibitor” NCT06343805 ↗ |
| Route | Oral | “taken orally by patients” NCT06343805 ↗ |
| Target | JAK2 | “Type II JAK2 inhibitor” NCT06343805 ↗ |